Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD


Small-cell lung carcinoma (SCLC) accounts for 20% of the total number of lung cancer cases worldwide. SCLC patients have limited treatment options, especially when they present with metastatic disease. During this year ASCO Meeting results from two trials were presented showing promising data on the application of immunotherapy with PD-1 agents to relapsed SCLC, bringing some hope for tackling the disease.

Read more

Regulatory T cells (Treg) are a specialized type of immune cells, crucial for the maintenance of immunological self-tolerance, the suppressive mechanisms thanks to which our body avoids self-destruction by an overactive immune system. Treg cells are also abundant in the tumor microenvironment where they can expand and differentiate into an immune-suppressive subpopulation. A study recently published on Science uncovered a new mechanism that allows Treg to keep a steady inhibition of the immune response, thereby protecting normal tissues. This mechanism could also be at play in the tumor microenvironment resulting in immune cells inhibition and tumor growth.

Read more

Antioxidants are compounds that decrease the levels of reactive oxygen species (ROS), a natural byproduct of cellular metabolism. ROS cause DNA damage, which in turn is associated with cancer. Thus antioxidants are widely marketed as dietary supplements with a variety of health claims, including the ability to decrease the risk of cancer. However, a number of studies, including some clinical trials have questioned this claim, suggesting that antioxidants may actually promote cancer development in susceptible individuals.

Read more

The U.S. Food and Drug Administration recently approved Tresiba (insulin degludec injection) and Ryzodeg (70% insulin degludec-30% insulin aspart injection) to improve blood glucose control in adult patients with type 1 and type 2 diabetes.

Read more